We are experiencing some temporary issues. The market data on this page is currently delayed.

ASX - Delayed Quote AUD

Recce Pharmaceuticals Ltd (RCE.AX)

0.3600 +0.0300 (+9.09%)

At close: 4:10:11 PM GMT+11

Chart Range Bar

Advanced Chart

AlphaSpace Chart

Loading chart for RCE.AX

Previous Close 0.3300
Open 0.3450
Bid 0.3550 x --
Ask 0.3600 x --
Day's Range 0.3450 - 0.3650
52 Week Range 0.2650 - 0.7300
Volume 10,314,707
Avg. Volume 98,240
Market Cap (intraday) 110.077M
Beta (5Y Monthly) 0.54
PE Ratio (TTM) --
EPS (TTM) -0.0500
Earnings Date (est.) --
Forward Dividend & Yield -- (0.00%)
Ex-Dividend Date --
1y Target Est 2.05

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic antiinfectives in Australia, the United Kingdom, and the United States. The company's lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis; and R327 Topical Gel, which is in Phase II clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as is in Phase III clinical trials for topical wound infections and diabetic foot infections. The company has strategic partnership with Murdoch Children's Research Institute for development of the Acinetobacter baumannii; and cooperative research and development agreement with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to be tested against highly hazardous pathogens. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.

www.recce.com.au

Full Time Employees

June 30

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recce's R327G gains commercial pathway with Arrotex

Recce Pharmaceuticals Ltd managing director and CEO James Graham talked with Proactive about the company’s exclusive licensing and commercialisation agreement with Arrotex Pharmaceuticals for RECCE® 327 topical gel (R327G) in Australia and New Zealand. Graham described the agreement as a significant step for Recce Pharmaceuticals, highlighting Arrotex’s pharmaceutical sales, marketing, distribution and market-access capabilities across Australia and New Zealand. He said the partnership allows each company to focus on its respective strengths as R327G progresses through clinical development. Graham also discussed Arrotex’s reach within Australia’s Pharmaceutical Benefits Scheme and across hospitals, clinics and pharmacies, describing the company as a strong commercialisation partner for R327G. Graham discussed clinical work underway in Indonesia as well as the company’s Australian Phase 3 study, with Australian data expected to be an important part of the regulatory pathway. He said the Indonesian study was already demonstrating what he described as a strong efficacy signal while maintaining an excellent safety profile. The Australian study remains underway, with further clinical data expected as the program advances. Looking ahead, Graham identified potential clinical data readouts, regulatory submissions and additional licensing opportunities in surrounding markets as important milestones for R327G. Visit Proactive’s YouTube channel for more interviews and updates from listed companies and industry leaders. If you found this video useful, give it a like, subscribe to the channel and enable notifications so you don’t miss future Proactive content. #ReccePharmaceuticals #RCE #RECEF #R327G #RECCE327 #ArrotexPharmaceuticals #DiabeticFootInfection #DFI #Phase3 #ClinicalTrials #Biotech #Pharmaceuticals #AntiInfectives #DrugDevelopment #Healthcare #ASX #Australia #NewZealand